Autologous adult stem cells (ASCs) are being administered by physicians for indications that
have not been demonstrated as safe and effective in formal clinical trials. Examination of
regulatory frameworks across five countries suggests that balancing the demands of
research with clinical freedom has created structural weaknesses that are being exploited.